Rapamycin: An anti-cancer immunosuppressant?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Vezina, 1975, Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle, J Antibiot (Tokyo), 28, 721, 10.7164/antibiotics.28.721
Sehgal, 1975, Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization, J Antibiot (Tokyo), 28, 727, 10.7164/antibiotics.28.727
Calne, 1989, Rapamycin for immunosuppression in organ allografting, Lancet, 2, 227, 10.1016/S0140-6736(89)90417-0
Thomson, 1989, Immunosuppressive properties of FK-506 and rapamycin, Lancet, 2, 443, 10.1016/S0140-6736(89)90616-8
Tocci, 1989, The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes, J Immunol, 143, 718, 10.4049/jimmunol.143.2.718
Heitman, 1991, Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast, Science, 253, 905, 10.1126/science.1715094
Brown, 1994, A mammalian protein targeted by G1-arresting rapamycin–receptor complex, Nature, 369, 756, 10.1038/369756a0
Sabatini, 1994, RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs, Cell, 78, 35, 10.1016/0092-8674(94)90570-3
Sabers, 1995, Isolation of a protein target of the FKBP12–rapamycin complex in mammalian cells, J Biol Chem, 270, 815, 10.1074/jbc.270.2.815
Gingras, 2001, Regulation of translation initiation by FRAP/mTOR, Genes Dev, 15, 807, 10.1101/gad.887201
Schmidt, 1998, The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the tryptophan permease, EMBO J, 17, 6924, 10.1093/emboj/17.23.6924
Beck, 1999, The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors, Nature, 402, 689, 10.1038/45287
Dumont, 1996, Mechanism of action of the immunosuppressant rapamycin, Life Sci, 58, 373, 10.1016/0024-3205(95)02233-3
von Manteuffel, 1997, The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k, Mol Cell Biol, 17, 5426, 10.1128/MCB.17.9.5426
Hara, 1998, Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism, J Biol Chem, 273, 14484, 10.1074/jbc.273.23.14484
Wang, 1998, Amino acid availability regulates p70 S6 kinase and multiple translation factors, Biochem J, 334, 261, 10.1042/bj3340261
Xu, 1998, Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic beta-cells. A possible role in protein translation and mitogenic signaling, J Biol Chem, 273, 28178, 10.1074/jbc.273.43.28178
Iiboshi, 1999, Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation, J Biol Chem, 274, 1092, 10.1074/jbc.274.2.1092
Peyrollier, 2000, l-Leucine availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the l-leucine-induced up-regulation of system A amino acid transport, Biochem J, 350, 361, 10.1042/0264-6021:3500361
Fang, 2001, Phosphatidic acid-mediated mitogenic activation of mTOR signaling, Science, 294, 1942, 10.1126/science.1066015
Wang, 2003, Inorganic polyphosphate stimulates mammalian TOR, a kinase involved in the proliferation of mammary cancer cells, Proc Natl Acad Sci USA, 100, 11249, 10.1073/pnas.1534805100
Corradetti, 2004, Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz–Jeghers syndrome, Genes Dev, 18, 1533, 10.1101/gad.1199104
Shaw, 2004, The LKB1 tumor suppressor negatively regulates mTOR signaling, Cancer Cell, 6, 91, 10.1016/j.ccr.2004.06.007
Bentley, 1996, The Schizosaccharomyces pombe rad3 checkpoint gene, EMBO J, 15, 6641, 10.1002/j.1460-2075.1996.tb01054.x
Cliby, 1998, Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints, EMBO J, 17, 159, 10.1093/emboj/17.1.159
Wright, 1998, Protein kinase mutants of human ATR increase sensitivity to UV and ionizing radiation and abrogate cell cycle checkpoint control, Proc Natl Acad Sci USA, 95, 7445, 10.1073/pnas.95.13.7445
Bierer, 1990, Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin, Proc Natl Acad Sci USA, 87, 9231, 10.1073/pnas.87.23.9231
Burnett, 1998, RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1, Proc Natl Acad Sci USA, 95, 1432, 10.1073/pnas.95.4.1432
Brunn, 1996, Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002, EMBO J, 15, 5256, 10.1002/j.1460-2075.1996.tb00911.x
Brunn, 1997, Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin, Science, 277, 99, 10.1126/science.277.5322.99
Withers, 1997, Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells, Biochem Biophys Res Commun, 241, 704, 10.1006/bbrc.1997.7878
Chung, 1992, Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q
Ferrari, 1993, The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites, J Biol Chem, 268, 16091, 10.1016/S0021-9258(19)85389-9
Graves, 1995, cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells, Proc Natl Acad Sci USA, 92, 7222, 10.1073/pnas.92.16.7222
Lin, 1995, Control of PHAS-I by insulin in 3T3-L1 adipocytes. Synthesis, degradation, and phosphorylation by a rapamycin-sensitive and mitogen-activated protein kinase-independent pathway, J Biol Chem, 270, 18531, 10.1074/jbc.270.31.18531
Hara, 2002, Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action, Cell, 110, 177, 10.1016/S0092-8674(02)00833-4
Kim, 2002, mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery, Cell, 110, 163, 10.1016/S0092-8674(02)00808-5
Kim, 2003, GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR, Mol Cell, 11, 895, 10.1016/S1097-2765(03)00114-X
Nojima, 2003, The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif, J Biol Chem, 278, 15461, 10.1074/jbc.C200665200
Schalm, 2003, TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function, Curr Biol, 13, 797, 10.1016/S0960-9822(03)00329-4
Inoki, 2002, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling, Nat Cell Biol, 4, 648, 10.1038/ncb839
Dan, 2002, Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin, J Biol Chem, 277, 35364, 10.1074/jbc.M205838200
Hong, 2003, Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases, Proc Natl Acad Sci USA, 100, 8839, 10.1073/pnas.1533136100
Hawley, 2003, Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade, J Biol, 2, 28, 10.1186/1475-4924-2-28
Woods, 2003, LKB1 is the upstream kinase in the AMP-activated protein kinase cascade, Curr Biol, 13, 2004, 10.1016/j.cub.2003.10.031
Shaw, 2004, The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress, Proc Natl Acad Sci USA, 101, 3329, 10.1073/pnas.0308061100
Inoki, 2003, Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling, Genes Dev, 17, 1829, 10.1101/gad.1110003
Tee, 2003, Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb, Curr Biol, 13, 1259, 10.1016/S0960-9822(03)00506-2
Zhang, 2003, Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins, Nat Cell Biol, 5, 578, 10.1038/ncb999
Garami, 2003, Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2, Mol Cell, 11, 1457, 10.1016/S1097-2765(03)00220-X
Fang, 2003, PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1, Curr Biol, 13, 2037, 10.1016/j.cub.2003.11.021
Chen, 2002, A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling, Biochem Pharmacol, 64, 1071, 10.1016/S0006-2952(02)01263-7
Ballou, 2003, Ca(2+)- and phospholipase D-dependent and -independent pathways activate mTOR signaling, FEBS Lett, 550, 51, 10.1016/S0014-5793(03)00816-0
Kam, 2004, Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid, Faseb J, 18, 311, 10.1096/fj.03-0731com
Pause, 1994, Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function, Nature, 371, 762, 10.1038/371762a0
Beretta, 1996, Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation, EMBO J, 15, 658, 10.1002/j.1460-2075.1996.tb00398.x
Haystead, 1994, Phosphorylation of PHAS-I by mitogen-activated protein (MAP) kinase. Identification of a site phosphorylated by MAP kinase in vitro and in response to insulin in rat adipocytes, J Biol Chem, 269, 23185, 10.1016/S0021-9258(17)31637-X
Hu, 1994, Molecular cloning and tissue distribution of PHAS-I, an intracellular target for insulin and growth factors, Proc Natl Acad Sci USA, 91, 3730, 10.1073/pnas.91.9.3730
Lin, 1994, PHAS-I as a link between mitogen-activated protein kinase and translation initiation, Science, 266, 653, 10.1126/science.7939721
Mothe-Satney, 2000, Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies, J Biol Chem, 275, 33836, 10.1074/jbc.M006005200
Price, 1989, Purification of a hepatic S6 kinase from cycloheximide-treated Rats, J Biol Chem, 264, 13825, 10.1016/S0021-9258(18)80075-8
Blenis, 1985, Regulation of a ribosomal protein S6 kinase activity by the Rous sarcoma virus transforming protein, serum, or phorbol ester, Proc Natl Acad Sci USA, 82, 7621, 10.1073/pnas.82.22.7621
Blenis, 1986, Regulation of protein kinase activities in PC12 pheochromocytoma cells, EMBO J, 5, 3441, 10.1002/j.1460-2075.1986.tb04667.x
Blenis, 1987, Identification of a ribosomal protein S6 kinase regulated by transformation and growth-promoting stimuli, J Biol Chem, 262, 14373, 10.1016/S0021-9258(18)47802-7
Jeno, 1988, Identification and characterization of a mitogen-activated S6 kinase, Proc Natl Acad Sci USA, 85, 406, 10.1073/pnas.85.2.406
Chung, 1994, PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase, Nature, 370, 71, 10.1038/370071a0
Pullen, 1998, Phosphorylation and activation of p70s6k by PDK1, Science, 279, 707, 10.1126/science.279.5351.707
Balendran, 1999, Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252, J Biol Chem, 274, 37400, 10.1074/jbc.274.52.37400
Shah, 2003, Mitotic regulation of ribosomal S6 kinase 1 involves Ser/Thr, Pro phosphorylation of consensus and non-consensus sites by Cdc2, J Biol Chem, 278, 16433, 10.1074/jbc.M300435200
Isotani, 1999, Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro, J Biol Chem, 274, 34493, 10.1074/jbc.274.48.34493
Pearson, 1995, The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain, EMBO J, 14, 5279, 10.1002/j.1460-2075.1995.tb00212.x
Wilson, 2000, Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex, J Biol Chem, 275, 37307, 10.1074/jbc.C000482200
Susa, 1992, Inhibition or down-regulation of protein kinase C attenuates late phase p70s6k activation induced by epidermal growth factor but not by platelet-derived growth factor or insulin, J Biol Chem, 267, 6905, 10.1016/S0021-9258(19)50514-2
Parekh, 1999, Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon, J Biol Chem, 274, 34758, 10.1074/jbc.274.49.34758
Kumar, 2000, Functional interaction between RAFT1/FRAP/mTOR and protein kinase cdelta in the regulation of cap-dependent initiation of translation, EMBO J, 19, 1087, 10.1093/emboj/19.5.1087
Akimoto, 1998, Atypical protein kinase Clambda binds and regulates p70 S6 kinase, Biochem J, 335, 417, 10.1042/bj3350417
Ziegler, 1999, Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex, Curr Biol, 9, 522, 10.1016/S0960-9822(99)80236-X
Kristof, 2003, Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin, J Biol Chem, 278, 33637, 10.1074/jbc.M301053200
Yokogami, 2000, Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR, Curr Biol, 10, 47, 10.1016/S0960-9822(99)00268-7
Rajan, 2003, BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells, J Cell Biol, 161, 911, 10.1083/jcb.200211021
James, 2004, Phosphatidylinositol-3 kinase and mTOR signaling pathways regulate RNA Polymerase I transcription in response to IGF-1 and nutrients, J Biol Chem, 279, 8911, 10.1074/jbc.M307735200
Schwartz, 2001, Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways, J Cell Sci, 114, 2553, 10.1242/jcs.114.14.2553
Albers, 1993, FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line, J Biol Chem, 268, 22825, 10.1016/S0021-9258(18)41602-X
Withers, 1997, Rapamycin dissociates p70(S6K) activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells, J Biol Chem, 272, 2509, 10.1074/jbc.272.4.2509
Hashemolhosseini, 1998, Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability, J Biol Chem, 273, 14424, 10.1074/jbc.273.23.14424
Law, 2000, Salicylate-induced Growth Arrest Is Associated with Inhibition of p70s6k and Down-regulation of c-Myc, Cyclin D1, Cyclin A, and Proliferating Cell Nuclear Antigen, J Biol Chem, 275, 38261, 10.1074/jbc.M005545200
Feng, 2000, Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-Kinase/p70 S6 kinase pathway in spermatogonia, J Biol Chem, 275, 25572, 10.1074/jbc.M002218200
Decker, 2003, Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin, Blood, 101, 278, 10.1182/blood-2002-01-0189
West, 1998, Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway, Oncogene, 17, 769, 10.1038/sj.onc.1201990
Nelsen, 2003, Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes, J Biol Chem, 278, 3656, 10.1074/jbc.M209374200
Feuerstein, 1995, Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte. Evidence for inhibition of CREB/ATF binding activities, J Biol Chem, 270, 9454, 10.1074/jbc.270.16.9454
Javier, 1997, Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells, J Clin Invest, 99, 2094, 10.1172/JCI119382
Jayaraman, 1993, Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line, J Biol Chem, 268, 25385, 10.1016/S0021-9258(19)74403-2
Morice, 1993, Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes, J Biol Chem, 268, 22737, 10.1016/S0021-9258(18)41589-X
Chen, 1996, The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G1-prolongation of NIH3T3 cells, Oncogene, 13, 1765
Chou, 2003, Cdc42 promotes G1 progression through p70 S6 kinase-mediated induction of cyclin E expression, J Biol Chem, 278, 35241, 10.1074/jbc.M305246200
Brennan, 1999, p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes, Mol Cell Biol, 19, 4729, 10.1128/MCB.19.7.4729
Law, 2002, Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells, Mol Cell Biol, 22, 8184, 10.1128/MCB.22.23.8184-8198.2002
Nourse, 1994, Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin, Nature, 372, 570, 10.1038/372570a0
Zezula, 1997, The cyclin-dependent kinase inhibitor p21cip1 mediates the growth inhibitory effect of phorbol esters in human venous endothelial cells, J Biol Chem, 272, 29967, 10.1074/jbc.272.47.29967
Vinals, 1999, p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation, J Biol Chem, 274, 26776, 10.1074/jbc.274.38.26776
Gaben, 2004, Rapamycin inhibits cdk4 activation, p21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts, Int J Cancer, 108, 200, 10.1002/ijc.11521
Harper, 1993, The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases, Cell, 75, 805, 10.1016/0092-8674(93)90499-G
Elbendary, 1994, Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells, Cell Growth Differ, 5, 1301
Huppi, 1994, Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1), Oncogene, 9, 3017
Polyak, 1994, p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest, Genes Dev, 8, 9, 10.1101/gad.8.1.9
Toyoshima, 1994, p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21, Cell, 78, 67, 10.1016/0092-8674(94)90573-8
Polyak, 1994, Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals, Cell, 78, 59, 10.1016/0092-8674(94)90572-X
LaBaer, 1997, New functional activities for the p21 family of CDK inhibitors, Genes Dev, 11, 847, 10.1101/gad.11.7.847
Zhang, 1994, p21-containing cyclin kinases exist in both active and inactive states, Genes Dev, 8, 1750, 10.1101/gad.8.15.1750
Cheng, 1999, The p21(Cip1) and p27(Kip1) CDK ’inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts, EMBO J, 18, 1571, 10.1093/emboj/18.6.1571
Muraoka, 2002, ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells, Mol Cell Biol, 22, 2204, 10.1128/MCB.22.7.2204-2219.2002
Luo, 1996, Rapamycin resistance tied to defective regulation of p27Kip1, Mol Cell Biol, 16, 6744, 10.1128/MCB.16.12.6744
Soucek, 1998, Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2, Proc Natl Acad Sci USA, 95, 15653, 10.1073/pnas.95.26.15653
Bouchard, 1999, Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27, EMBO J, 18, 5321, 10.1093/emboj/18.19.5321
Perez-Roger, 1999, Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1), EMBO J, 18, 5310, 10.1093/emboj/18.19.5310
Tsutsui, 1999, Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity, Mol Cell Biol, 19, 7011, 10.1128/MCB.19.10.7011
Grewe, 1999, Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells, Cancer Res, 59, 3581
Takuwa, 1999, Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts, Mol Cell Biol, 19, 1346, 10.1128/MCB.19.2.1346
Bodner, 1999, Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1), Gene, 229, 223, 10.1016/S0378-1119(98)00591-5
Kato, 1993, Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4, Genes Dev, 7, 331, 10.1101/gad.7.3.331
Adnane, 1999, Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcription, Oncogene, 18, 239, 10.1038/sj.onc.1202297
Martel, 1977, Inhibition of the immune response by rapamycin, a new antifungal antibiotic, Can J Physiol Pharmacol, 55, 48, 10.1139/y77-007
Eng, 1984, Activity of rapamycin (AY-22, 989) against transplanted tumors, J Antibiot (Tokyo), 37, 1231, 10.7164/antibiotics.37.1231
Dumont, 1990, Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin, J Immunol, 144, 251, 10.4049/jimmunol.144.1.251
Wicker, 1990, Suppression of B cell activation by cyclosporin A, FK506 and rapamycin, Eur J Immunol, 20, 2277, 10.1002/eji.1830201017
Kay, 1991, Inhibition of T and B lymphocyte proliferation by rapamycin, Immunology, 72, 544
Woltman, 2003, Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression, Blood, 101, 1439, 10.1182/blood-2002-06-1688
Dumont, 1990, The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells, J Immunol, 144, 1418, 10.4049/jimmunol.144.4.1418
Fruman, 1992, Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A, Proc Natl Acad Sci USA, 89, 3686, 10.1073/pnas.89.9.3686
Liu, 1992, Inhibition of T cell signaling by immunophilin–ligand complexes correlates with loss of calcineurin phosphatase activity, Biochemistry, 31, 3896, 10.1021/bi00131a002
Kuo, 1992, Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase, Nature, 358, 70, 10.1038/358070a0
Calvo, 1992, Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin, Proc Natl Acad Sci USA, 89, 7571, 10.1073/pnas.89.16.7571
O’Keefe, 1992, FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin, Nature, 357, 692, 10.1038/357692a0
Peng, 2002, The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation, Mol Cell Biol, 22, 5575, 10.1128/MCB.22.15.5575-5584.2002
Luan, 2002, Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy, Transplantation, 73, 1565, 10.1097/00007890-200205270-00008
Stegall, 2003, Kidney transplantation without calcineurin inhibitors using sirolimus, Transplant Proc, 35, 125S, 10.1016/S0041-1345(03)00226-4
Nair, 2003, Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients, Liver Transplant, 9, 126, 10.1053/jlts.2003.50026
Flechner, 2003, Minimizing calcineurin inhibitor drugs in renal transplantation, Transplant Proc, 35, 118S, 10.1016/S0041-1345(03)00218-5
Flechner, 2002, Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine, Transplantation, 74, 1070, 10.1097/00007890-200210270-00002
Reis, 2002, Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection, Cornea, 21, 81, 10.1097/00003226-200201000-00017
Seufferlein, 1996, Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells, Cancer Res, 56, 3895
Moore, 1998, The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway, Cancer Res, 58, 5239
Couch, 1999, Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer, Cancer Res, 59, 1408
Barlund, 2000, Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis, J Natl Cancer Inst, 92, 1252, 10.1093/jnci/92.15.1252
Dilling, 2002, 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin, J Biol Chem, 277, 13907, 10.1074/jbc.M110782200
Rosenwald, 1993, Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E, Mol Cell Biol, 13, 7358, 10.1128/MCB.13.12.7358
De Benedetti, 1999, eIF4E expression in tumors: its possible role in progression of malignancies, Int J Biochem Cell Biol, 31, 59, 10.1016/S1357-2725(98)00132-0
Rosenwald, 1999, Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis, Oncogene, 18, 2507, 10.1038/sj.onc.1202563
Li, 1997, Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma, Cancer, 79, 2385, 10.1002/(SICI)1097-0142(19970615)79:12<2385::AID-CNCR13>3.0.CO;2-N
Li, 1998, Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression, Ann Surg, 227, 756, 10.1097/00000658-199805000-00016
Nathan, 1997, Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer, Oncogene, 15, 579, 10.1038/sj.onc.1201216
Smith, 1990, Translation initiation factors induce DNA synthesis and transform NIH 3T3 cells, New Biol, 2, 648
Rousseau, 1996, The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth, Oncogene, 13, 2415
Miyagi, 1995, Elevated levels of eukaryotic translation initiation factor eIF-4E, mRNA in a broad spectrum of transformed cell lines, Cancer Lett, 91, 247, 10.1016/0304-3835(95)03737-H
Green, 1994, Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients, Nat Genet, 6, 193, 10.1038/ng0294-193
Green, 1994, The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor, Hum Mol Genet, 3, 1833, 10.1093/hmg/3.10.1833
Sampson, 1994, The molecular genetics of tuberous sclerosis, Hum Mol Genet, 3, 1477, 10.1093/hmg/3.suppl_1.1477
Cairns, 1997, Frequent inactivation of PTEN/MMAC1 in primary prostate cancer, Cancer Res, 57, 4997
Dahia, 1997, Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors, Cancer Res, 57, 4710
Wang, 1997, Somatic mutations of PTEN in glioblastoma multiforme, Cancer Res, 57, 4183
Liu, 1997, PTEN/MMAC1 mutations and EGFR amplification in glioblastomas, Cancer Res, 57, 5254
Cairns, 1998, Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers, Oncogene, 16, 3215, 10.1038/sj.onc.1201855
Kim, 1998, Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines, Oncogene, 16, 89, 10.1038/sj.onc.1201512
Kohno, 1998, Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers, Genes Chromosomes Cancer, 22, 152, 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S
Levine, 1998, PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma, Cancer Res, 58, 3254
Obata, 1998, Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors, Cancer Res, 58, 2095
Aveyard, 1999, Somatic mutation of PTEN in bladder carcinoma, Br J Cancer, 80, 904, 10.1038/sj.bjc.6690439
Alimov, 1999, Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma, Anticancer Res, 19, 3841
Di Cristofano, 1998, Pten is essential for embryonic development and tumour suppression, Nat Genet, 19, 348, 10.1038/1235
Suzuki, 1998, High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice, Curr Biol, 8, 1169, 10.1016/S0960-9822(07)00488-5
Podsypanina, 1999, Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems, Proc Natl Acad Sci USA, 96, 1563, 10.1073/pnas.96.4.1563
Stambolic, 2000, High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/− mice, Cancer Res, 60, 3605
Kwabi-Addo, 2001, Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression, Proc Natl Acad Sci USA, 98, 11563, 10.1073/pnas.201167798
Li, 2002, Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland, Development, 129, 4159, 10.1242/dev.129.17.4159
Trotman, 2003, Pten dose dictates cancer progression in the prostate, PLoS Biol, 1, 59, 10.1371/journal.pbio.0000059
Hemminki, 1997, Localization of a susceptibility locus for Peutz–Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis, Nat Genet, 15, 87, 10.1038/ng0197-87
Hemminki, 1998, A serine/threonine kinase gene defective in Peutz–Jeghers syndrome, Nature, 391, 184, 10.1038/34432
Wang, 1999, Germline mutations of the LKB1 (STK11) gene in Peutz–Jeghers patients, J Med Genet, 36, 365
Su, 1999, Germline and somatic mutations of the STK11/LKB1 Peutz–Jeghers gene in pancreatic and biliary cancers, Am J Pathol, 154, 1835, 10.1016/S0002-9440(10)65440-5
Guldberg, 1999, Somatic mutation of the Peutz–Jeghers syndrome gene, LKB1/STK11, in malignant melanoma, Oncogene, 18, 1777, 10.1038/sj.onc.1202486
Rowan, 1999, Somatic mutations in the Peutz–Jeghers (LKB1/STKII) gene in sporadic malignant melanomas, J Invest Dermatol, 112, 509, 10.1046/j.1523-1747.1999.00551.x
Wang, 1999, Allele loss and mutation screen at the Peutz–Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours, Br J Cancer, 80, 70, 10.1038/sj.bjc.6690323
Sanchez-Cespedes, 2002, Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung, Cancer Res, 62, 3659
Carretero, 2004, Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene, Oncogene, 23, 4037, 10.1038/sj.onc.1207502
Esteller, 2000, Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz–Jeghers syndrome, Oncogene, 19, 164, 10.1038/sj.onc.1203227
Shen, 2002, The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma, Clin Cancer Res, 8, 2085
Nakau, 2002, Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice, Cancer Res, 62, 4549
Houchens, 1983, Human brain tumor xenografts in nude mice as a chemotherapy model, Eur J Cancer Clin Oncol, 19, 799, 10.1016/0277-5379(83)90012-3
Dudkin, 2001, Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition, Clin Cancer Res, 7, 1758
Geoerger, 2001, Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy, Cancer Res, 61, 1527
Yu, 2001, mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer, Endocr Relat Cancer, 8, 249, 10.1677/erc.0.0080249
Neshat, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc Natl Acad Sci USA, 98, 10314, 10.1073/pnas.171076798
Podsypanina, 2001, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice, Proc Natl Acad Sci U S A, 98, 10320, 10.1073/pnas.171060098
Grunwald, 2002, Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells, Cancer Res, 62, 6141
Shi, 2002, Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779, Cancer Res, 62, 5027
Gera, 2004, AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression, J Biol Chem, 279, 2737, 10.1074/jbc.M309999200
Penuel, 1999, Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways, Mol Biol Cell, 10, 1693, 10.1091/mbc.10.6.1693
Louro, 1999, The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin, Cell Growth Differ, 10, 503
Aoki, 2001, A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt, Proc Natl Acad Sci USA, 98, 136, 10.1073/pnas.011528498
Nomura, 2003, Involvement of the Akt/mTOR pathway on EGF-induced cell transformation, Mol Carcinog, 38, 25, 10.1002/mc.10140
Boulay, 2004, Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells, Cancer Res, 64, 252, 10.1158/0008-5472.CAN-3554-2
Peralba, 2003, Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients, Clin Cancer Res, 9, 2887
Raymond, 2004, Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer, J Clin Oncol, 22, 2336, 10.1200/JCO.2004.08.116
Atkins, 2004, Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma, J Clin Oncol, 22, 909, 10.1200/JCO.2004.08.185
Guba, 2002, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, 8, 128, 10.1038/nm0202-128
Knighton, 1977, Avascular and vascular phases of tumour growth in the chick embryo, Br J Cancer, 35, 347, 10.1038/bjc.1977.49
Yu, 1999, MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor, J Cell Physiol, 178, 235, 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.0.CO;2-S
Zhong, 2000, Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics, Cancer Res, 60, 1541
Treins, 2002, Obberghen Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway, J Biol Chem, 277, 27975, 10.1074/jbc.M204152200
Mayerhofer, 2002, BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin, Blood, 100, 3767, 10.1182/blood-2002-01-0109
Hudson, 2002, Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin, Mol Cell Biol, 22, 7004, 10.1128/MCB.22.20.7004-7014.2002
Marx, 2001, Bench to bedside: the development of rapamycin and its application to stent restenosis, Circulation, 104, 852, 10.1161/01.CIR.104.8.852
Sousa, 2001, Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study, Circulation, 103, 192, 10.1161/01.CIR.103.2.192
Grube, 2004, Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer, Circulation, 109, 2168, 10.1161/01.CIR.0000128850.84227.FD
Law, 2000, Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli, J Biol Chem, 275, 10796, 10.1074/jbc.275.15.10796
Law, 1999, Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway, J Biol Chem, 274, 4743, 10.1074/jbc.274.8.4743
Castro, 2003, Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner, J Biol Chem, 278, 32493, 10.1074/jbc.C300226200
Iiboshi, 1999, l-Asparaginase inhibits the rapamycin-targeted signaling pathway, Biochem Biophys Res Commun, 260, 534, 10.1006/bbrc.1999.0920
Ly, 2003, Bcr–Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin, Cancer Res, 63, 5716
Mohi, 2004, Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs, Proc Natl Acad Sci USA, 101, 3130, 10.1073/pnas.0400063101
Fukazawa, 2000, U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways, Cancer Res, 60, 2104
Eshleman, 2002, Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy, Cancer Res, 62, 7291
Shi, 1995, Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro, Cancer Res, 55, 1982
van der Poel, 2003, Rapamycin induces Smad activity in prostate cancer cell lines, Urol Res, 30, 380, 10.1007/s00240-002-0282-1